Vitreoretinal Surgery Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Vitreoretinal Surgery Devices Market Trends and Insights

Rising Prevalence of Diabetic Retinopathy & AMD

Diabetic retinopathy affected 103.12 million adults in 2025, while age-related macular degeneration reached 195.92 million cases, creating a durable pipeline for complex retinal procedures. China’s Healthy China 2030 program increased rural retinal screening coverage to 54% by 2025, resulting in a 22% boost in newly diagnosed proliferative cases.^{[1]National Health Commission China, “Healthy China 2030 Screening Update,” nhc.gov.cn} India’s National Programme for Control of Blindness reported that diabetic eye disease prevalence climbed to 21.3 % among known diabetics in 2025, lengthening specialist wait times in tier-2 cities. In North America, rising obesity rates sustain incident diabetes, keeping procedure backlogs elevated. These epidemiological trends are driving the expansion of the vitreoretinal surgery devices market, as hospitals and ASCs invest in additional consoles and consumables to meet the growing demand.

Shift Toward Single-Use Ophthalmic Instruments Driven by Strict Infection-Control Mandates

The 2024 CDC guideline reclassified reusable endo-illuminators as critical devices that require sterilization between cases, a standard many sterile-processing departments struggle to meet. U.S. retina services responded by shifting to pre-sterilized disposable light pipes and cutters, prompting a 41% surge in Alcon’s disposable sales during Q3 2025. The EU Medical Device Regulation’s traceability rules added paperwork for reusables, accelerating the adoption of single-use products in high-volume centers in Germany and France. Bausch + Lomb’s Stellaris Elite platform capitalized on the trend by bundling 25-gauge disposable packs that eliminate reprocessing liability, capturing 18% of the U.S. ASC segment in 2025. As urban APAC hospitals emulate Western infection-control standards, the penetration of single-use products is rising in Singapore, Seoul, and tier-1 Chinese cities.

Expansion of Outpatient/ASC Vitreoretinal Procedures

Medicare removed multiple vitrectomy codes from the inpatient-only list in 2025, allowing ASCs to bill at 58% of hospital outpatient rates while retaining higher margins.^{[2]Centers for Medicare & Medicaid Services, “Physician Fee Schedule 2025,” cms.gov} ASC vitrectomy volume in the United States jumped 27% year-over-year through Q1 2026, with SCA Health opening 14 retina-focused centers outfitted for 90-minute turnovers. Saudi Arabia licensed 22 private day-surgery units in 2025, mirroring the U.S. shift. However, European ASC penetration remains below 15% because of licensing hurdles and bundled hospital contracts. The migration concentrates volume in high-throughput facilities that favor standardized, disposable kits, thereby expanding the addressable demand for vitreoretinal surgery devices.

Intra-Operative OCT & Digital Visualization Uptake

Carl Zeiss Meditec’s RESCAN 700 and Leica’s EnFocus Ultra, cleared in 2024, integrated spectral-domain OCT into surgical microscopes, reducing repeat membrane-peel rates by 23% in complex proliferative cases. Alcon’s NGENUITY 3D display reached 22% penetration in U.S. academic centers by late 2025, cutting surgeon neck strain by 40% during 8-hour lists. Japan’s aging ophthalmologist workforce values ergonomic heads-up display, supporting early adoption. High capital premiums, ranging from USD 150,000 to USD 200,000 above standard scopes, remain a barrier; however, leasing models and bundled service contracts are helping to improve affordability. The technology’s ability to shorten operative time and avoid re-interventions reinforces its pull on the vitreoretinal surgery devices market.

High Capital & Consumable Costs

A fully configured vitrectomy suite costs USD 250,000 to USD 450,000, a figure that excludes 68% of U.S. independent retina practices from ownership.^{[3]American Society of Retina Specialists, “Practice Survey 2025,” asrs.org} Single-use packs add USD 800 to USD 1,200 per case, versus USD 200 to USD 300 for reusables after reprocessing labor, straining margins in low-income markets. In India, consumables account for 42% of procedure costs, which limits adoption in tier-2 and tier-3 cities, where out-of-pocket payments dominate. DORC’s EVA NEXUS, launched at USD 180,000, aims to bridge the gap with modular upgrades but commands slow uptake, as surgeons prioritize entrenched Alcon and Bausch ecosystems. While leasing models, such as Alcon’s OptiLease, spread costs over 36 months, only 10% of practices have adopted them due to the perceived risk of obsolescence.

Patchy Reimbursement for Premium Kits

The 2025 Medicare ASC payment for CPT 67036 is USD 1,847, barely covering basic micro-incision disposables and leaving no room for intra-operative OCT add-ons. Private U.S. insurers frequently classify disposable light pipes as bundled supplies, denying separate payment. Germany’s DRG pays EUR 2,100 (USD 2,289) but requires onerous documentation to bill for 27-gauge upgrades. The United Kingdom’s flat GBP 1,620 (USD 2,041) tariff has frozen since 2024, forcing National Health Service trusts to ration advanced visualization tools. Manufacturers have begun to implement value-based contracts Bausch + Lomb, for example, cuts 15% off the list price in exchange for shared savings on readmissions to overcome payor resistance.

Segment Analysis

By Product Type: Consumables Gain as Systems Mature

Single-use consumables expanded their share of the vitreoretinal surgery devices market in 2025, growing at a 6.76% annual rate, while vitrectomy consoles accounted for 34.81% of the revenue. Prefilled silicone-oil syringes trimmed eight minutes of prep time per case and cut contamination risk, propelling adoption among ASCs focused on fast turnover. Endo-illumination is shifting toward disposable LED light pipes, with 58% of Bausch’s 2025 sales projected to come from single-use units. Perfluorocarbon liquids remain a niche but steady earner; Vitreq’s extended-duration formulation, CE Marked in 2024, lengthened tamponade dwell time and postponed follow-up surgeries.

The momentum of consumables hinges on infection-control mandates and the economics of ASCs, where reprocessing space is at a premium. The vitreoretinal surgery devices market size for disposables is projected to widen further as CDC and EU regulators scrutinize reusable validation data. Meanwhile, console vendors stress backward compatibility; Alcon’s Unity system allows legacy Constellation owners to migrate gradually by adding disposable gauge-specific cassettes. Carl Zeiss Meditec bundles microscopes with OCT modules to secure long-term consumable revenue, mirroring the printer-ink razor model that stabilizes cash flow.

Note: Segment shares of all individual segments available upon report purchase

By Surgery Type: Anterior Segment Work Accelerates

Posterior procedures continued to dominate, accounting for 69.03% of the revenue in 2025; however, anterior vitrectomy volumes increased by 7.20% annually due to pediatric trauma and cataract-related complications. The vitreoretinal surgery devices market size for anterior cases benefits from cross-utilizing the same 27-gauge cutters used posteriorly, minimizing inventory SKUs for ASCs. A 27-gauge anterior approach cut surgical time by 12 minutes compared to a 20-gauge approach, lowering anesthesia exposure in children and aligning with ASC session economics. Posterior cases, although slower-growing, account for 82% of consumable spend, as they require more forceps, scissors, and retinal tamponades.

Medicare’s 2025 site-neutral reforms further erased inpatient-outpatient divides, encouraging same-day discharge even for posterior repairs. Ophthalmologists increasingly refer complex anterior complications to retina specialists, concentrating volume in high-throughput centers that specify disposable kits. BVI and Katalyst Surgical now offer sub-USD 400 anterior vitrectomy packs that align with payor bundles, reinforcing consumable tailwinds for the vitreoretinal surgery devices market.

By Technology: Micro-Incision Dominance Masks Conventional Resurgence

Twenty-five-gauge and twenty-seven-gauge platforms held a 78.43% share in 2025 due to the appeal of sutureless wounds; however, lower-cost 20-/23-gauge consoles are rebounding at 5.91% in price-sensitive APAC and Latin American sites. A meta-analysis showed that 27-gauge vitrectomy reduced hypotony to 1.2% compared to 3.8% for 20-gauge, yet the latter remains essential for thick membrane manipulation and large foreign-body removal. Indian eye-care chains deploy 20-gauge systems in rural satellites, where reusable instruments align with budget constraints. The vitreoretinal surgery devices market continues to prioritize hybrid consoles; Alcon’s Unity offers interchangeable gauge cassettes, allowing clinics to tailor costs to case complexity.

EU regulators have slowed the introduction of ultra-small-gauge products, those with 30-gauge and narrower diameters, as manufacturers must demonstrate non-inferiority to 27-gauge. This regulatory drag could prolong revenue for established gauges, giving suppliers time to amortize R&D. Meanwhile, robotic trocar placement systems from Preceyes promise to standardize port alignment regardless of gauge, potentially flattening the learning curve and enlarging addressable demand.

Note: Segment shares of all individual segments available upon report purchase

By End User: ASCs Capture Margin-Conscious Volume

Hospitals retained a 42.46% share in 2025, but ASC volumes are expanding at an 8.52% annual rate, driven by a 28%-34% lower cost per case and surgeon equity incentives. SCA Health and Surgery Partners added 31 retina-dedicated centers in 2025, each configured for 12-16 daily cases and stocked exclusively with pre-sterilized instrument packs. The vitreoretinal surgery devices market size associated with ASCs is, therefore, the fastest-growing channel. In Europe and Japan, restrictive licensing maintains hospital dominance, but policy debates are intensifying as payers scrutinize U.S. savings benchmarks.

Ophthalmology clinics remain a niche but noteworthy end-user: portable systems, such as MedOne’s Photon, priced at USD 120,000, enable in-office floaterectomies. Reimbursement uncertainty, however, caps growth. Alcon’s 36-month lease at USD 6,500 per month aims to bridge capital barriers, yet adoption lags amid concerns about technological obsolescence. Nonetheless, any acceleration in clinic-based procedures would open an additional front in the vitreoretinal surgery devices market.

Geography Analysis

North America accounted for 39.16% of 2025 revenue, anchored by Medicare’s willingness to reimburse digital visualization and high ASC penetration. The United States alone placed 230 new vitrectomy consoles in 2025, with 64% of these going to ASCs. Canada continues to favor hospital outpatient departments but is trialing bundled-payment pilots that could speed ASC licensing by 2027. 

Asia-Pacific is the fastest-growing territory, advancing at a 7.74% CAGR through 2031. Medical tourism drew 47,200 inbound ophthalmic cases to Thailand in 2025, while India’s National Health Mission funded 140 district-hospital vitrectomy systems that same year. China’s NHSA cataloged 12 reimbursable retinal codes in 2025, reimbursing 85% of the patient's cost and igniting demand for consoles in tier-2 urban clusters. Collectively, these initiatives expand the vitreoretinal surgery devices market and shift unit placement growth toward APAC.

Europe’s growth is hindered by flat DRG tariffs and stringent EU MDR rules, which extend approval timelines and delay the launch of new-gauge and single-use products. Backlog pressures in Germany, the United Kingdom, and France are pushing clinics in Eastern Europe to adopt lower-cost 23-gauge systems, which could moderate regional ASPs. The Middle East and Africa are growing at a rate of 6.2% per year, buoyed by the Gulf Cooperation Council's hospital privatization and South Africa’s expansion of its private-hospital network. South America faces currency volatility; Brazil’s public SUS system reimburses only basic 20-gauge kits, shifting premium demand to self-pay urban clinics. Australia, while minor, approved intra-operative OCT for reimbursement in 2025, underscoring its early-adopter profile.